
Sign up to save your podcasts
Or


Dr Lori Wirth from the Massachusetts General Hospital in Boston discusses the latest clinical data and ongoing investigations on targeted therapeutic approaches for the management of RET-altered and NTRK fusion-positive thyroid cancers.
CME information and select publications here.
By Research To Practice5
66 ratings
Dr Lori Wirth from the Massachusetts General Hospital in Boston discusses the latest clinical data and ongoing investigations on targeted therapeutic approaches for the management of RET-altered and NTRK fusion-positive thyroid cancers.
CME information and select publications here.

66 Listeners

30 Listeners

75 Listeners

14 Listeners

17 Listeners

4 Listeners

2 Listeners

12 Listeners

0 Listeners

122 Listeners